TUNE-401 gives Tune Therapeutics an early signal in the race for finite HBV therapy
Find out how Tune Therapeutics’ TUNE-401 data could reshape the chronic hepatitis B cure race and what risks remain for Phase 2.
Pharma & Biotech
Pharma & Biotech
Rubedo takes cellular rejuvenation into actinic keratosis with early RLS-1496 results
Rubedo’s RLS-1496 shows early actinic keratosis lesion reduction with low irritation. Find out why Phase 2b matters next.